Research programme: influenza virus transcriptase inhibitors - Shire

Drug Profile

Research programme: influenza virus transcriptase inhibitors - Shire

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator ViroPharma
  • Class
  • Mechanism of Action DNA-directed RNA polymerase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 22 Apr 1999 Preclinical development for Influenza virus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top